Vogenx

General Information
Business:	(Incorporated in Delaware) We are a Phase 2 clinical biotech developing drugs to treat endocrine and metabolic disorders. Our focus is on post-bariatric hypoglycemia (PBH) and gastroparesis. Our lead product candidate, mizagliflozin, is an oral drug candidate (a pill) in development in a Phase 2B study to treat post-bariatric hypoglycemia. Mizaglifozin is a minimally absorbed selective small molecule inhibitor of SGLT1 (sodium-glucose transporter 1), a glucose transporter in the GI tract responsible for transporting dietary glucose into the bloodstream. We have licensed mizaglifozin from Kissei Pharmaceutical on a worldwide basis, excluding Japan, Korea and Taiwan. We are also planning a Phase 2 proof-of-concept clinical trial of mizaglifozin in patients diagnosed with gastroparesis. We expect to start this trial in 2027, subject to additional funding. We anticipate submitting an Investigational New Drug (IND) application to the FDA in 2027 for use of mizagliflozin in patients diagnosed with GIP-dependent Cushing’s Syndrome (GDCS). Our pre-clinical small molecule candidate, VGX-2857, is being considered for metabolic disease indications, including weight maintenance. Note: Net loss is for the 12 months that ended on March 31, 2026. The company has never generated any revenue, according to the prospectus. (Note: Vogenx disclosed the terms for its IPO on July 29, 2026, in an S-1/A filing: 6.25 million shares at a price range of $11.00 to $13.00 to raise $75 million. Background: Vogenx filed its S-1 for its IPO on July 15, 2026, without disclosing the terms. Estimated IPO proceeds were $75 million.)
Industry:	Pharmaceuticals
Employees:	5
Founded:	2021
Contact Information
Address	PO Box 19469 Raleigh, North Carolina 27619
Phone Number	(919) 659-5677
Web Address	https://www.vogenx.com/
View Prospectus:	Vogenx
Financial Information
Market Cap	$166.87mil
Revenues	$0.0 mil (last 12 months)
Net Income	$-1.56 mil (last 12 months)
IPO Profile
Symbol	VOGX
Exchange	NASDAQ
Shares (millions):	6.3
Price range	$11.00 - $13.00
Est. $ Volume	$75.0 mil
Manager / Joint Managers	JonesTrading
CO-Managers
Expected To Trade:	8/6/2026
Day:	Thursday
Quiet Period Expiration Date:	Available only to Subscribers
Lock-Up Period Expiration Date:	Available only to Subscribers
SCOOP Rating	Available only to Subscribers
Rating Change	Available only to Subscribers

Vogenx

(Incorporated in Delaware)

We are a Phase 2 clinical biotech developing drugs to treat endocrine and metabolic disorders. Our focus is on post-bariatric hypoglycemia (PBH) and gastroparesis.

Our lead product candidate, mizagliflozin, is an oral drug candidate (a pill) in development in a Phase 2B study to treat post-bariatric hypoglycemia.

Mizaglifozin is a minimally absorbed selective small molecule inhibitor of SGLT1 (sodium-glucose transporter 1), a glucose transporter in the GI tract responsible for transporting dietary glucose into the bloodstream.

We have licensed mizaglifozin from Kissei Pharmaceutical on a worldwide basis, excluding Japan, Korea and Taiwan.

We are also planning a Phase 2 proof-of-concept clinical trial of mizaglifozin in patients diagnosed with gastroparesis. We expect to start this trial in 2027, subject to additional funding.

We anticipate submitting an Investigational New Drug (IND) application to the FDA in 2027 for use of mizagliflozin in patients diagnosed with GIP-dependent Cushing’s Syndrome (GDCS).

Our pre-clinical small molecule candidate, VGX-2857, is being considered for metabolic disease indications, including weight maintenance.

Note: Net loss is for the 12 months that ended on March 31, 2026. The company has never generated any revenue, according to the prospectus.

(Note: Vogenx disclosed the terms for its IPO on July 29, 2026, in an S-1/A filing: 6.25 million shares at a price range of $11.00 to $13.00 to raise $75 million. Background: Vogenx filed its S-1 for its IPO on July 15, 2026, without disclosing the terms. Estimated IPO proceeds were $75 million.)